Journal Mobile Options
Table of Contents
Vol. 77, No. 2, 2008
Issue release date: April 2008
Digestion 2008;77:87–91

Extract of Radix Curcumae Prevents Gastric Cancer in Rats

Lu B. · Xu L. · Yu L. · Zhang L.
Department of Gastroenterology, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: Radix curcumae is a Chinese medicinal herb commonly used in the treatment of malignancy. This study was to investigate the chemopreventive effect of an extract solution from radix curcumae in a rat model of gastric cancer induced by N-methyl-N′-nitro-N-nitrosoguanidine (MNNG). Methods: Eighty male Wistar rats were randomly allocated to 5 groups administered different agents for 40 weeks: group A, water and normal saline; group B, MNNG and normal saline; group C, MNNG and celecoxib; group D, MNNG and low-dose (1 g/ml) radix curcumae steam distillation extract solution; group E, MNNG and high-dose (2 g/ml) radix curcumae wet distillation extract solution. At the end of week 40, all rats alive were sacrificed. Gastric cancer and precancerous lesions in the stomach were evaluated by histology. Results: In total there were 35 deaths during the study period. The incidences of gastric cancer were 0.0% (0/16) in group A, 44.4% (7/16) in group B, 12.5% (2/16) in group C, 12.5% (2/16) in group D and 12.5% (2/16) in group E. Tumor incidence and tumor volume were significantly lower in groups C, D and E compared to those in group B (p < 0.05). There was no significant difference of tumor incidence and tumor volume among groups C, D and E (p = 1.000). Conclusion: Extract solution from radix curcumae obtained by the steam distillation procedure has a chemopreventive effect on gastric cancer induced by MNNG in rats.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Xia HH, Wong BC, Lam SK: Chemoprevention of gastric cancer: current status. Chin Med J 2003;116:5–10.
  2. Parkin DM, Bray F, Ferlay J, et al: Global Cancer Statistics, 2002. CA Cancer J Clin 2005,55:74–108.
  3. Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006;12:17–20.

    External Resources

  4. Khan FA, Shukla AN: Pathogenesis and treatment of gastric carcinoma: an update with brief review. J Cancer Res Ther 2006;2:196–199.
  5. Correa P, Fontham ET, Bravo JC, et al: Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-Helicobacter pylori therapy. J Natl Cancer Inst 2000;92:1881–1888.
  6. Nardone G, Rocco A: Chemoprevention of gastric cancer: role of COX-2 inhibitors and other agents. Dig Dis Sci 2004;22:320–326.

    External Resources

  7. Wang WH, Huang JQ, Zheng GF, et al: Non-steroidal anti-inflammatory drug use and the risk of gastric cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2003;95:1784–1791.
  8. Sung JJ, Lin SR, Ching JY, et al: Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000;119:7–14.
  9. Zhou L, Sung JJ, Lin S, et al: A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chin Med J (Engl) 2003;116:11–14.
  10. Zhu S, Mason J, Shi Y, et al: The effect of folic acid on the development of stomach and other gastrointestinal cancers. Chin Med J (Engl) 2003;116:15–19.
  11. Zullo A, Rinaldi V, Hassan C, et al: Ascorbic acid and intestinal metaplasia in the stomach: a prospective, randomized study. Aliment Pharmacol Ther 2000;14:1303–1309.
  12. Bjelakovic G, Nikolova D, Simonetti RG, et al: Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004;364:1219–1228.
  13. Wong BC, Lam SK, Wong WM, et al: Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187–194.
  14. Hu PJ, Yu J, Zeng ZR, et al: Chemoprevention of gastric cancer by celecoxib in rats. Gut 2004;53:195–200.
  15. Zhang L, Lu H, Liu WZ, et al: Effect of nimesulide on chemoprevention of N-ethyl-N-nitro-N-nitrosoguanidine induced gastric cancer in rat model. Chin J Dig 2003;23:391–394.
  16. Goel A, Boland CR, Chauhan DP: Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001;172:111–118.
  17. Arbiser JL, Klauber N, Rohan R, et al: Curcumin is an in vivo inhibitor of angiogenesis. Mol Med 1998;4:376–383.
  18. Jon M, Holy JM: Curcumin disrupts mitotic spindle structure and induces micronucleation in MCF-7 breast cancer cells. Mutat Res 2002;518:71–84.
  19. Squires MS, Hudson EA, Howells L, et al: Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells. Biochem Pharmacol 2003;65:361–376.
  20. Chen A, Xu J: Activation of PPAR-gamma by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol 2005;288:G447–G456.
  21. Wang JL, Lu B, Ni GB, et al: Effect of common gurmeric on vascular endothelial growth factor and microvessel density in athymic mouse model transplanted with human gastric carcinoma. Tumor 2005;25:55–57.
  22. Xu Y, Lu B, Xiang BK, et al: Effect of extract of radix curcumae on somatostatin in plasma and gastric tissue. Chin J Integr Trad West Med Gastrospleen 2004;12:222–224.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50